Ocular Oncology and Pathology

Sodhi G.S.a· Singh N.b· Wrenn J.a· Singh A.D.a

Author affiliations

aCleveland Clinic, Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland, OH, USA
bMass Eye and Ear Infirmary, Boston, MA, USA

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: September 29, 2022
Accepted: November 22, 2022
Published online: December 14, 2022

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 3

ISSN: 2296-4681 (Print)
eISSN: 2296-4657 (Online)

For additional information: https://www.karger.com/OOP

Abstract

Introduction: Peripheral exudative hemorrhagic chorioretinopathy (PEHCR) is one of the leading mimickers of choroidal melanoma because of overlapping features with choroidal melanoma that make the distinction between these two entities difficult. Methods: To identify nonoverlapping diagnostic features between PEHCR and choroidal melanoma, a retrospective study of 80 patients (80 eyes); 40 patients (40 eyes) with PEHCR; and 40 patients (40 eyes) with choroidal melanoma was conducted. Ophthalmoscopic and imaging features of PEHCR and choroidal melanoma were compared. Sensitivity and specificity for identifying PEHCR and choroidal melanoma were calculated. Youden’s J statistic was assessed for each diagnostic feature. Results: The most frequent clinical features of PEHCR were presence of druse (100%), hemorrhagic PED (93%), dome-shaped mass (B-scan) (90%), and subretinal/intraretinal hemorrhage (78%). Statistical analysis confirmed high sensitivity of hemorrhagic PED (0.93; 95% CI 0.80–0.98) and high specificity of clot retraction cleft, presence of lipid exudation, and bilaterality (1.00; 95% CI 0.91–1.00) as diagnostic features of PEHCR. Statistical analysis revealed presence of subretinal fluid 0.80 (95% CI 0.54–0.91) was most sensitive and presence of orange pigment, mushroom shape on B-scan, ciliary body extension, and choroidal excavation were most specific (1.00; 95% CI 0.91–1.00) for choroidal melanoma. Nonoverlapping diagnostic features of PEHCR were hemorrhagic PED, clot retraction cleft, presence of lipid exudation, and bilaterality. All PEHCR patients (100%) had at least one of these nonoverlapping diagnostic features. Nonoverlapping diagnostic features of choroidal melanoma were the presence of orange pigment, choroidal excavation, mushroom-shaped mass, and ciliary body extension (the latter 3 detected on B-scan). Youden’s J statistic was highest for hemorrhagic PED and lowest for dome-shape appearance on B-scan (0.075). Conclusion: PEHCR and choroidal melanoma can be differentiated by identifying diagnostic features that are exclusive to each entity. The presence of hemorrhagic PED strongly supports a diagnosis of PEHCR. B-scan ultrasonography is required to detect a mushroom-shaped mass, choroidal excavation, or ciliary body extension to exclude underlying choroidal melanoma.

© 2022 S. Karger AG, Basel

References Shields CL, Salazar PF, Mashayekhi A, Shields JA. Peripheral exudative hemorrhagic chorioretinopathy simulating choroidal melanoma in 173 eyes. Ophthalmology. 2009 Mar;116(3):529–35. Mantel I, Uffer S, Zografos L. Peripheral exudative hemorrhagic chorioretinopathy: a clinical, angiographic, and histologic study. Am J Ophthalmol. 2009 Dec;148(6):932–8.e1. Annesley WH Jr. Peripheral exudative hemorrhagic chorioretinopathy. Trans Am Ophthalmol Soc. 1980;78:321–64. Shields JA, Mashayekhi A, Ra S, Shields CL. Pseudomelanomas of the posterior uveal tract: the 2006 Taylor R. Smith Lecture. Retina. 2005 Sep;25(6):767–71. Mantel I, Schalenbourg A, Zografos L. Peripheral exudative hemorrhagic chorioretinopathy: polypoidal choroidal vasculopathy and hemodynamic modifications. Am J Ophthalmol. 2012 May;153(5):910–22.e2. Mashayekhi A, Shields CL, Shields JA. Peripheral exudative hemorrhagic chorioretinopathy: a variant of polypoidal choroidal vasculopathy? J Ophthalmic Vis Res. 2013 Jul;8(3):264–7. Goldman DR, Freund KB, McCannel CA, Sarraf D. Peripheral polypoidal choroidal vasculopathy as a cause of peripheral exudative hemorrhagic chorioretinopathy: a report of 10 eyes. Retina. 2013 Jan;33(1):48–55. Tsui I, Jain A, Shah S, Schwartz SD, McCannel TA. Ultra widefield imaging of peripheral exudative hemorrhagic chorioretinopathy. Semin Ophthalmol. 2009 Jan-Feb;24(1):25–8. Shields JA, Augsburger JJ, Brown GC, Stephens RF. The differential diagnosis of posterior uveal melanoma. Ophthalmology. 1980 Jun;87(6):518–22. Bardenstein DS, Char DH, Irvine AR, Stone RD. Extramacular disciform lesions simulating uveal tumors. Ophthalmology. 1992 Jun;99(6):944–51. Zografos LS, A. Uveal melanoma: clinical features. In: Damato BS, A D, editors. Uveal tumors. Switzerland: Springer; 2019. p. 46–8. Larrea J, Sánchez-Ávila RM, Villota-Deleu E, Fernández-Vega Sanz A. Clinical characteristics of peripheral exudative hemorrhagic chorioretinopathy in a referral center in Spain. Arch Soc Esp Oftalmol. 2022;97(11):603–11. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–5. Chang M, Zimmerman LE, McLean I. The persisting pseudomelanoma problem. Arch Ophthalmol. 1984 May;102(5):726–7. Ghassemi F, Bazvand F, Hosseini SS. Pseudomelanoma at a referral center in Iran. J Ophthalmic Vis Res. 2014 Jan;9(1):50–3. Singh AD, Medina CA, Singh N, Aronow ME, Biscotti CV, Triozzi PL. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol. 2016 Apr;100(4):456–62. Vandefonteyne S, Caujolle JP, Rosier L, Conrath J, Quentel G, Tadayoni R, et al. Diagnosis and treatment of peripheral exudative haemorrhagic chorioretinopathy. Br J Ophthalmol. 2020 Jun;104(6):874–8. Ahuja RM, Stanga PE, Vingerling JR, Reck AC, Bird AC. Polypoidal choroidal vasculopathy in exudative and haemorrhagic pigment epithelial detachments. Br J Ophthalmol. 2000 May;84(5):479–84. Zicarelli F, Preziosa C, Staurenghi G, Pellegrini M. Peripheral exudative haemorrhagic chorioretinopathy: a widefield imaging study. Br J Ophthalmol. 2021 Oct;105(10):1410–4. Badawi AH, Semidey VA, Magliyah M, Al-Dhibi H. Updated systematic review and clinical spectrum of peripheral exudative hemorrhagic chorioretinopathy. Middle East Afr J Ophthalmol. 2020 Jan–Mar;27(1):4–9. Scott JF, Vyas R, Galvin J, Gotow E, Fiessinger L, Gerstenblith AT, et al. Primary bilateral uveal melanoma: a population-based study and systematic review. Clin Exp Ophthalmol. 2018 Jul;46(5):502–10. Shields CL, Shields JA, Kiratli H, De Potter P, Cater JR. Risk factors for growth and metastasis of small choroidal melanocytic lesions. Ophthalmology. 1995 Sep;102(9):1351–61. Singh AD, Mokashi AA, Bena JF, Jacques R, Rundle PA, Rennie IG. Small choroidal melanocytic lesions: features predictive of growth. Ophthalmology. 2006 Jun;113(6):1032–9. Garcia MD, Salomao DR, Marmorstein AD, Pulido JS. Histopathologic findings in the areas of orange pigment overlying choroidal melanomas. Transl Vis Sci Technol. 2016 May;5(3):4. Roelofs KA, O'Day R, Harby LA, Arora AK, Cohen VML, Sagoo MS, et al. The MOLES system for planning management of melanocytic choroidal tumors: is it safe? Cancers. 2020 May 21;12(5):1311. Shields JA, Shields CL, Brown GC, Eagle RC Jr. Mushroom-shaped choroidal metastasis simulating a choroidal melanoma. Retina. 2002 Dec;22(6):810–3. Robertson DM, Campbell RJ, Salomao DR. Mushroom-shaped choroidal melanocytoma mimicking malignant melanoma. Arch Ophthalmol. 2002 Jan;120(1):82–5. Turell MH, Schoenfield L, Singh AD. Intraocular tumors. In: Singh ADH, editors. Ophthalmic ultrasonography. China: Elsevier Saunders; 2012. p. 120–3. Article / Publication Details

First-Page Preview

Received: September 29, 2022
Accepted: November 22, 2022
Published online: December 14, 2022

Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 3

ISSN: 2296-4681 (Print)
eISSN: 2296-4657 (Online)

For additional information: https://www.karger.com/OOP

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.